The object of this study was to determine the effect of triflusal (UR-1501), a new potential antithrombotic agent, on hemostasis (blood coagulation and platelet aggregation induced by ADP and collagen) in man. The trials were carried out during seven days with 5 male healthy volunteers, aged 20 to 25, and with 20 patients of either sex, aged 30 to 66, with latent thromboembolic diseases or with high risk thereof. The healthy volunteers and one group of 10 patients were treated only with triflusal (300 mg orally, 30 minutes before the three principal meals). The other group of 10 patients was treated with triflusal (same dose) jointly with Sintrom. The results show an augmentation of anticoagulant effect of Sintrom by triflusal (decrease of prothrombin time and increase of activated partial thromboplastin time, both statistically significant) and a significant decrease of the platelet adhesiveness and of the potential thrombodynamic index (PTI) in the group of patients treated with both drugs. A clear inhibitory effect of triflusal on platelet aggregation induced by ADP and collagen has also been observed in all studied groups. The results suggest an interest in the new compound triflusal for the prophylaxis and treatment of thromboembolic diseases and in the cases of high thrombotic risk.
|Journal||Current Therapeutic Research - Clinical and Experimental|
|Publication status||Published - 1 Jan 1977|